RENEWED APPROACH TO THE DIAGNOSIS AND TREATMENT OF THE RHEUMATOID ARTHRITIS IN EARLY STAGES
Keywords:
rheumatoid arthritis, diagnostics, treatment, basic anti-inflammatory drugs, combined therapyAbstract
The importance of timely and correct diagnosis of RA, its differentiation from reactive arthritis and other joint diseases can hardly be overestimated, since the correct tactics at the onset of the disease determine the nature of the course of arthritis, the progression of joint destruction and functional joint failure. The problem of accurate early diagnosis of RA, which is inextricably linked with the study of the immediate and long-term outcomes of the disease, is currently especially relevant, due to the possibility of slowing down the development of the disease with the help of modern methods of treatment, if the therapy is started early. At the same time early development of adequate basal combined pharmacotherapy early rheumatoid arthritis reduces the severity of the clinical manifestations of RA, improves functional activity and retards radiographic progression of joint damage, reducing the risk of disability and significantly improves the economic efficiency of the treatment of rheumatoid arthritis.
References
Karateev D.E., Luchikhina E.L. Modern principles of rheumatoid arthritis treatment: focus on early aggressive therapy. // Effect. pharmakoter. rheumatol. traumatol. orthopedist. - 2017.- N 1. - pp.12–17.
Kilani, R.T., Maksimovich, V.P., Aitken, A.G., Boire, Saint-Pierre Yu. (2017) High levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid in patients with joint inflammation. J Rheumatol 34 (8): pp.1650-1657.
Maximovich V.P., Landewe R, vanderHeijde D, etal. (2016) Serum 14-3-3η: biomarker-cer of rheumatoid arthritis [ACR / ARHP Abstract S358]. Art Reum 73 (Annex 10): p.358.
Maximovich V.P., Van der Heide D.M., Allaart K.F., Landewe R., Boiret G. et al. (2015) 14-3-3eta - new mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. ArthritisResTher 16 (2): R99.
Mazurov V.I. Clinical Rheumatology. // Manual for physicians. -2015.- p.520. 6. Muradyants A.A. Early rheumatoid arthritis: clinical-laboratory and instrumental aspects of diagnostics. (in Russian) // Autoref. of dis. on juice candidate of medical sciences. Yaroslavl. -2018. -p. 29.
Nasonova E.L. Rheumatology: clinical recommeUDAtions. // М.- 2016. - pp. 90–230.
Shostak, N.A.; Muradyants, A.A. Early rheumatoid arthritis: diagnostic and treatment algorithms (in Russian) // M.-2017.- pp. 82–106. 9. Yaremenko, O.B. Diagnostics of rheumatoid arthritis at early stages. // Kiev. - 2018.- pp. 82-106. 9. Pp.63-65.
Yaremenko, O.B. B. Basis therapy of rheumatoid arthritis. // Materials of Ukrainian rheumatological school. - – 2012. - pp. 94–115. 11. American Intercollegiate of rheumatologists. Recommendations for use of basic anti-inflammation preperations and Biologic agents in rheumatoid arthritis. // Clinical pharmacology and therapy. - 2019.- Vol. 18, N 1. - Р. 43.
Calguneri M., Pay S., Caliskaner Z. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. // Clin. exp. rheumatol.- 2019. Vol. 17. - Р. 699–704.
Chavez-Munoz C, Kilani RT, Ghahary A (2019) Profile of proteins associated with exosomes that are isolated by differentiated and undifferentiated human keratinocytes. J CellPhysiol 221 (1): pp.221-231.
Cohen S.B., Emery P.А., Greenwald M.W., Dougados M.К., Furie R.A., Genovese M.C., Keystone E.C., Loveless J.E., Burmester G.R., Cravets M.W., Hessey E.W., Shaw T.Т., Totoritis M.C.; Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double–blind, placebo–controlled, phase III trial evaluating primary efficacy and safety at twenty four weeks. // Arthritis rheum.- 2016.- Vol. 9, N 54.- Р. 2793–2806.
Tashpulatova M.M., Nabiyeva D.A., Sagatova D.R., Askarov N. 14-3-3 (eta) protein as a new biomarker in rheumatoid arthritis//International Journal ofAdvanced Science and Technology Vol.29.-№ 5(2020) pp.1871-1877
Emery P., Breedveld F. C., Dougados M. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. // Ann. rheum. dis. – 2012. – Vol. 61, N 4. – pp. 290–297.
Emery P., Breedveld F.C., Hall S. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis //Lancet.- 2018.-Vol. 372. -pp.375–382.
Katchamart W., Bourre-Tessier J., Donka T. Canadian Recommendations for Use of Methotrexate in Patients with Rheumatoid Arthritis. // J. rheumatol.- 2018.- Vol.7, N 37. - pp.1422–1430.
Kosta P.E., Voulgari P.V., Zikou A.K. The usefulness of magnetic resonance imaging of the hand and wrist in very early rheumatoid arthritis. // Arth. res. ther.-2017. Vol.13, N 10.- Р. 1186. 20. Mjaavatten M.D., Haugen A.J., Helgetveit K. Pattern of joint involvement and other disease characteristics of 364 patients with arthritis of less than 16 weeks’ duration. //J. rheumatol.- 2019.- Vol. 36. - Р.1401–1406.
Moreland L.W., O'Dell J.R., Paulus H.E. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. // Arthritis rheum.- 2012. Vol. 64.- Р. 2824–2835.
Saag K.G., Teng G.G., Patkar N.M. RecommeUDAtions for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in Rheumatoid Arthritis. //Arthr. care and res.- 2018.- Vol. 59.- Р.762–784.
